Effective antitumor therapy based on a novel antibody-drug conjugate targeting the Tn carbohydrate antigen

Area of Science:

• Oncology
• Immunology
• Drug Development

Background:

• Antibody-drug conjugates (ADC) merge monoclonal antibody (mAb) specificity with cytotoxic drug power for cancer treatment.
• The Chi-Tn mAb targets a specific tumor-associated antigen, showing potential for ADC development.

Purpose of the Study:

• To evaluate the potential of the Chi-Tn mAb as an ADC for cancer therapy.
• To assess the in vivo targeting, internalization, and in vitro/in vivo efficacy of Chi-Tn-based ADCs.

Main Methods:

• In vivo tumor cell targeting studies.
• Flow cytometry and deconvolution microscopy for mAb internalization and localization.
• In vitro cytotoxicity assays with saporin (SAP) and auristatin F conjugates.
• In vivo antitumor activity assessment of Chi-Tn-auristatin F ADC.

Main Results:

• Chi-Tn mAb demonstrated specific in vivo tumor targeting.
• Rapid internalization and endosomal targeting of Chi-Tn mAb were observed.
• Chi-Tn ADCs showed effective in vitro cytotoxicity against Tn-positive tumor cells, correlating with Tn expression.
• Chi-Tn mAb conjugated to auristatin F exhibited significant in vivo antitumor efficacy.

Conclusions:

• The Chi-Tn mAb is a promising candidate for ADC development.
• Chi-Tn-based ADCs demonstrate effective tumor targeting, internalization, and cytotoxicity.
• This study validates the use of anti-Tn antibodies in effective ADC cancer therapy.